FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Leon Francisco
2. Issuer Name and Ticker or Trading Symbol

Provention Bio, Inc. [ PRVB ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Chief Scientific Officer
(Last)          (First)          (Middle)

C/O PROVENTION BIO, INC., P.O. BOX 666
3. Date of Earliest Transaction (MM/DD/YYYY)

7/15/2020
(Street)

OLDWICK, NJ 08858
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Option (right to buy) $12.62 7/15/2020  A   137750     (1)7/15/2030 Common Stock, par value $0.0001 137750 $0 (2)137750 D  

Explanation of Responses:
(1) 55,100 option shares vest in four equal annual installments commencing on July 15, 2021; the remaining 82,650 options shares vest upon completion of certain performance milestones. The completion of each milestone vests 15% of the total option shares.
(2) The securities were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Leon Francisco
C/O PROVENTION BIO, INC., P.O. BOX 666
OLDWICK, NJ 08858


Chief Scientific Officer

Signatures
/s/ Andrew Drechsler, as attorney-in-fact7/16/2020
**Signature of Reporting PersonDate

Provention Bio (NASDAQ:PRVB)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Provention Bio Charts.
Provention Bio (NASDAQ:PRVB)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Provention Bio Charts.